These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8001411)

  • 1. [The prospect of biologic therapy in ovarian cancer].
    Qian HN
    Zhonghua Fu Chan Ke Za Zhi; 1994 Jul; 29(7):386-8. PubMed ID: 8001411
    [No Abstract]   [Full Text] [Related]  

  • 2. Biological therapy of ovarian cancer: current directions.
    Bookman MA
    Semin Oncol; 1998 Jun; 25(3):381-96. PubMed ID: 9633851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunobiology and immunotherapy of ovarian cancer.
    Bookman MA; Bast RC
    Semin Oncol; 1991 Jun; 18(3):270-91. PubMed ID: 1710393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer.
    Bast RC; Xu F; Yu Y; Crews J; Argon Y; Maier L; Lidor Y; Berchuck A; Boyer CM
    Immunol Ser; 1994; 61():23-30. PubMed ID: 7912111
    [No Abstract]   [Full Text] [Related]  

  • 5. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
    Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
    Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic therapy for ovarian cancer.
    Bookman MA
    Curr Opin Oncol; 1989 Oct; 1(1):112-8. PubMed ID: 2489941
    [No Abstract]   [Full Text] [Related]  

  • 7. A case of recurrent ovarian cancer successfully treated with adoptive immunotherapy and lentinan.
    Fujimoto K; Tomonaga M; Goto S
    Anticancer Res; 2006; 26(6A):4015-8. PubMed ID: 17195451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
    Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
    Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic therapy in the management of refractory ovarian cancer.
    Bookman MA
    Gynecol Oncol; 1993 Oct; 51(1):113-26. PubMed ID: 8244165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
    Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
    Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic therapy and immunotherapy for ovarian cancer.
    Bookman MA
    Curr Opin Oncol; 1991 Oct; 3(5):901-7. PubMed ID: 1751581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for ovarian cancer.
    Bookman MA
    Curr Opin Oncol; 1990 Oct; 2(5):893-900. PubMed ID: 2095893
    [No Abstract]   [Full Text] [Related]  

  • 13. Adoptive immunotherapy of ovarian carcinoma.
    de Gramont A; Gangji D; Louvet C; Garcia ML; Tardy D; Romet-Lemonne JL
    Gynecol Oncol; 2002 Jul; 86(1):102-3. PubMed ID: 12079309
    [No Abstract]   [Full Text] [Related]  

  • 14. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model.
    Yoon SH; Lee JM; Cho HI; Kim EK; Kim HS; Park MY; Kim TG
    Cancer Gene Ther; 2009 Jun; 16(6):489-97. PubMed ID: 19096447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
    Melani C; Figini M; Nicosia D; Luison E; Ramakrishna V; Casorati G; Parmiani G; Eshhar Z; Canevari S; Colombo MP
    Cancer Res; 1998 Sep; 58(18):4146-54. PubMed ID: 9751627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic models in ovarian cancer].
    Tomov S; Gorchev G; Tsingilev D; Khinkova N
    Akush Ginekol (Sofiia); 2007; 46(5):22-7. PubMed ID: 17974178
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes.
    Ikarashi H; Fujita K; Takakuwa K; Kodama S; Tokunaga A; Takahashi T; Tanaka K
    Cancer Res; 1994 Jan; 54(1):190-6. PubMed ID: 8261438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer.
    Chiriva-Internati M; Weidanz JA; Yu Y; Frezza EE; Jenkins MR; Kennedy RC; Cobos E; Kast WM
    J Immunother; 2008 Oct; 31(8):693-703. PubMed ID: 18779750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing the immune system for ovarian cancer therapy.
    Odunsi K; Sabbatini P
    Am J Reprod Immunol; 2008 Jan; 59(1):62-74. PubMed ID: 18154597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.